Treating Erectile Dysfunction in Renal Transplant Recipients.[Miscellaneous Article]
2007/6/27
| Accession Number | 00003495-200767070-00003. |
|---|---|
| Author | Barry, John M |
| Institution | Division of Urology and Renal Transplantation, The Oregon Health and Science University, Portland, Oregon, USA |
| Title | Treating Erectile Dysfunction in Renal Transplant Recipients.[Miscellaneous Article] |
| Source | Drugs. 67(7):975-983, 2007. |
| Abstract | Erectile dysfunction is common in male kidney transplant recipients. Interference with the physiology of erections can be attributed to recipient co-morbidities, the renal transplant operation, medication adverse effects, relationship problems and changes in mental health. A treatment-oriented evaluation of erectile dysfunction allows the development of treatment plans that are patient-specific. Hypo-gonadal men whose hormone parameters do not improve after renal transplantation may respond to testosterone replacement therapy. Use of recommended doses of the phosphodiesterase-5 inhibitor sildenafil does not significantly modify trough concentrations of the calcineurin inhibitors ciclosporin and tacrolimus or result in impaired renal allograft function. Tacrolimus has been shown to increase the peak concentration and prolong the elimination half-life of sildenafil in kidney transplant recipients. Daily administration of sildenafil has resulted in decreased blood pressure in kidney transplant recipients with treated hypertension and tacrolimus immunosuppression. Intracavernosal injections of alprostadil, with or without papaverine and phentolamine, are effective treatments for erectile dysfunction after renal transplantation and have not resulted in alterations of ciclosporin concentrations or in deterioration of renal function. Penile prostheses can be successfully implanted after pelvic organ transplantation without significant risk of infection. Copyright 2007 Adis Data Information BV |
| Author Keywords | Alprostadil, therapeutic use; Erectile dysfunction, treatment; Renal transplant; Sildenafil, therapeutic use; Testosterone, therapeutic use; Vardenafil, therapeutic use. |
| References | 1. Rebollo P, Ortega F, Valdes C, et al. Influence of erectile dysfunction on health related quality of life of male kidney transplant patients. Int J Impot Res 2004; 16: 282-7 2. Malavaud B, Rostaing L, Rischmann P, et al. High prevalence of erectile dysfunction after renal transplantation. Transplantation 2000; 69: 2121-4 3. Lasaponara F, Paradiso M, Milan MG, et al. Erectile dysfunction after kidney transplantation: our 22 years of experience. Transplant Proc 2004; 36: 502-4 4. Russo D, Musone D, Alteri V, et al. Erectile dysfunction in kidney transplanted patients: efficacy of sildenafil. J Nephrol 2004; 17: 291-5 5. Feldmann HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61 6. Christ GJ, Lue T. Physiology and biochemistry of erections. Endocrine 2004; 23: 93-100 7. Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol and Med 2006; 231: 154-65 8. Barry JM. Male sexuality in renal transplant recipients. Transplant Immunol News 2000; 16: 7-13 9. El-Bahnsawy MS, El-Assmy A, Dawood A, et al. Effect of the use of internal iliac artery for renal revascularization on penile vascularity and erectile function: a prospective study. J Urol 2004; 172: 2335-9 10. Gittes RF, Waters WB. Sexual impotence: the overlooked complication of a second renal transplant. J Urol 1979; 121: 719-20 11. Karacan I. Clinical value of nocturnal erection in the prognosis and diagnosis of impotence. Med Aspects Hum Sex 1970; 4: 27-34 12. Thase ME, Reynolds CF, Jennings JR, et al. Diagnostic performance of nocturnal penile tumescence studies in healthy, dysfunctional (impotent), and depressed men. Psychiatry Res 1988; 26: 79-87 13. Barry JM, Blank BH, Boileau M. Nocturnal penile tumescence monitoring with stamps. J Urol 1980; 15: 171-2 14. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocrine Pract 2002; 8: 440-56 15. Rhoden EL, Estrada C, Levine L, et al. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003; 170: 795-8 16. Fritsche L, Budde K, Dragun D, et al. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004; 4: 130-1 17. Kantarci G, Sahin S, Uras AR, et al. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. Transplant Proc 2004; 36: 178-9 18. Wespes E, Wildschutz T, et al. The place for surgery for vascular impotence in the third millennium. J Urol 2003; 170: 1284-6 19. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65 (6): 773-86 20. Sharma RK, Prasad N, Gupta A, et al. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis 2006; 48: 128-33 21. Barrou B, Cuzin B, Malavaud B, et al. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 411-7 22. Prieto Castro RM, Anglada Curado FJ, Regueiro Lopez JC, et al. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. Br J Urol Int 2001; 88: 241-3 23. Cofan F, Gutierrez R, Beardo P, et al. Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction. Nefrologica 2002; 22: 470-6 24. Zhang Y, Guan DL, Ou TW, et al. Sildenafil citrate treatment for erectile dysfunction after kidney transplantation. Transplant Proc 2005; 37: 2100-3 25. Christ B, Brockmeier D, Hauck E, et al. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. Urology 2001; 58: 589-93 26. Rostaing L, Tran-Van T, Ader JL. Increased glomerular filtration rate in kidney transplant recipients who take sildenafil. N Engl J Med 2000; 342: 1679-80 27. Demir E, Balal M, Paydas S, et al. Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. Transplant Proc 2006; 38: 1379-81 28. Mansi MK, Alkhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159: 1927-30 29. Kim SC, Chang IH, Jeon HJ. Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 year. Br J Urol Int 2003; 92: 277-80 30. Abouseif SR, Breza J, Ruud JL, et al. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates. J Urol 1989; 142: 403-8 31. Levine SB, Althof LA, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54-7 32. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil afladex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized crossover. Urology 2000; 55: 109-13 33. Cuellar DC, Sklar GN. Penile prosthesis in organ transplant recipient. Urology 2001; 57: 138-41 |
| Language | English. |
| Document Type | Therapy In Practice. |
| Journal Subset | Clinical Medicine. |
| ISSN | 0012-6667 |
| NLM Journal Code | ec2, 7600076 |